US Dollar - USD
800-225-8238
Search Site

TAILGATE TALKS

A Tenacious Blog

Smoke signals are passé, newspapers are for packing up your glassware, and landlines are going extinct. So if you want the skinny on safety, you better check in with Tailgate Talks™ - a blog that covers latest in safety news, trends, regulations, and more.

19 Jul 11

Ergodyne Hosts Successful Safety Industry Fundraiser



Share on Facebook0Tweet about this on Twitter0Google+0Share on LinkedIn0
ergodyne-65-roses

St. Paul, Minn. (July 19, 2011) – Ergodyne hosted its fourteenth annual premiere 65 Roses Golf Classic: A Tenacious Tournament on Monday, July 18, 2011. The event brought together leading safety manufacturers, including 3M, Sqwincher, Brady Worldwide, Inc., and Accuform Signs as well as many other distributors, reps, and end users to raise money for the Cystic Fibrosis Foundation (CFF). Title sponsors included 3M, Superior 3rd Party Logistics, and the Votel Family Foundation.
This year, the 65 Roses Golf Classic: A Tenacious Tournament hosted 29 foursomes. The event included lunch, dinner and 18-holes of golf, as well as fabulous prizes, games, raffle items, and a live auction. Top auction items included two X-Games VIP passes, an Aspen dream vacation, a 2009 Polaris Ranger XP, a French Riviera Trip, and a one week stay in Quechee Lakes, Vermont.

“The fourteenth annual 65 Roses Golf Classic was a rousing success. With the help of friends, family, and the safety community, we netted over $175,000 for CF research,” said Tom Votel, CEO and President of Ergodyne. “That means that over the past fourteen years, we have raised more than $2.2 million dollars for this very worthy cause.”

At the dinner and live auction last night, Tom Votel spoke to why this year is an especially important one for the CF community: In February 2011, the CFF announced the successful completion of Phase 3 clinical trials on a revolutionary drug, VX-770, that actually corrects the basic genetic defect of CF.

This drug is expected to come to market in 2012 and will correct CF for 4% of the patient population. Not far behind, another drug is in the pipeline that addresses the most common CF gene mutation. When achieved, 94% of those with CF would have their disease “fixed” for good.

“Monumental strides have been made, but we still have work to do,” said Votel. “Bottom line: money buys science and science buys life.” For more information on this drug and other advances in Cystic Fibrosis, please visit www.cff.org.

About Cystic Fibrosis

Cystic Fibrosis is an inherited chronic disease that affects the lungs and digestive system of about 30,000 children and adults in the United States (70,000 worldwide). A defective gene and its protein product cause the body to produce unusually thick, sticky mucus that clogs the lungs and leads to life-threatening lung infections; and obstructs the pancreas and stops natural enzymes from helping the body break down and absorb food.

About the Cystic Fibrosis Foundation

The mission of the Cystic Fibrosis Foundation is to assure the development of the means to cure and control cystic fibrosis and to improve the quality of life for those with the disease. For more information on cystic fibrosis, call (800) FIGHT CF or visit our website at: www.cff.org.

About Ergodyne

Since 1983, Ergodyne has pioneered the development of products that Make The Workplace A Betterplace. What started with just one product has grown into a line of top flight, battle-tested, Tenacious Work Gear®; all precision crafted to manage the elements, improve productivity and provide protection for workers on jobsites the world over. The current lineup is extensive and constantly growing: ProFlex® Hand Protection, ProFlex® Knee Pads, ProFlex® Supports, Skullerz® Head Protection, Skullerz® Eye Protection, Trex™ Footwear Accessories, Chill-Its® Cooling Products, N-Ferno® Warming Products, GloWear® Hi-Vis Apparel, Squids® Lanyards, Arsenal® Equipment Storage Systems, and CORE Performance Work Wear® and SHAX® Portable Work Shelters.